Heparitin Sulfate

• 

  Subject Areas on Research

  • "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. 
  • A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke. 
  • A role for a lithium-inhibited Golgi nucleotidase in skeletal development and sulfation. 
  • A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. 
  • Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. 
  • Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. 
  • Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy. 
  • Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. 
  • Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. 
  • Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. 
  • Growth factor control of extracellular proteolysis. 
  • Heparan sulfate is a plasma biomarker of acute cellular allograft rejection. 
  • Heparan sulfate signaling in cancer. 
  • Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. 
  • Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration. 
  • Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. 
  • Intravenous fluid resuscitation is associated with septic endothelial glycocalyx degradation. 
  • Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation. 
  • Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. 
  • Large-dose infusions of heparinoid ORG 10172 in ischemic stroke. 
  • Mechanism of Fibronectin Binding to Human Trabecular Meshwork Exosomes and Its Modulation by Dexamethasone. 
  • Murine parietal endoderm cells synthesise heparan sulphate and 170K and 145K sulphated glycoproteins as components of Reichert's membrane. 
  • New treatment options for heparin-induced thrombocytopenia. 
  • Oxidized lipid-mediated alterations in proteoglycan metabolism in cultured pulmonary endothelial cells. 
  • Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. 
  • Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 
  • Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. 
  • Quantification of Glycosaminoglycans in Urine by Isotope-Dilution Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry. 
  • Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry. 
  • Studies of Org 10172 in patients with acute ischemic stroke. TOAST Study Group. 
  • Superfibronectin, a multimeric form of fibronectin, increases HIV infection of primary CD4+ T lymphocytes. 
  • The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening. 
  • Viscoelastic response of a model endothelial glycocalyx. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology